Grey Wolf Therapeutics Secures $49 Million for Cancer Research
Grey Wolf Therapeutics, a pioneering biotechnology company based in Oxford, UK, has made significant strides in the field of anti-tumour immunology. Recently, the company successfully raised $49 million in a Series B funding round aimed at bolstering its research and development initiatives. This substantial financial backing was led by prominent investors such as Pfizer Ventures and Earlybird Venture Capital, highlighting the confidence these firms have in Grey Wolf’s innovative approach to cancer treatment. Additional participation came from esteemed entities such as Oxford Science Enterprises, British Patient Capital, and returning investors Canaan and Andera Partners, further strengthening the company's investment network.
As part of this funding initiative, Grey Wolf Therapeutics has also welcomed several new members to its board of directors.
Among these distinguished appointments are Sally Dewhurst, a senior associate at Oxford Science Enterprises; Emma Johnson, an investment manager at British Patient Capital; Rabab Nasrallah, a principal at Earlybird Venture Capital; and Marie-Claire Peakman, a principal at Pfizer Ventures. These new board members bring a wealth of expertise and experience that will be invaluable as the company aims to advance its therapeutic strategies. The funds raised will primarily be directed towards advancing the company's immuno-oncology technologies, particularly focusing on overcoming critical resistance mechanisms associated with traditional cancer therapies through the creation of novel cancer antigens.
Leading the charge is Peter Joyce, Ph.D., the chief executive officer of Grey Wolf Therapeutics. The company’s unique approach targets the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which are crucial players in the antigen presentation pathway. By inhibiting these enzymes, Grey Wolf seeks to generate novel cancer antigens and upregulate other neoantigens, activating a brand-new T cell response that not only enhances tumour visibility but also circumvents the hurdles posed by current immunotherapies when T cells become exhausted. The flagship candidate, GRWD5769, is poised to begin Phase 1/2 clinical trials in the first half of 2023, promising a potentially transformative move toward more effective cancer treatments. Alongside it, another program focusing on ERAP2 inhibition is making steady progress through the discovery phase, marking a bright future for Grey Wolf Therapeutics in the evolving landscape of cancer immunotherapy.
They've invested in Grey Wolf Therapeutics
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Pfizer Ventures( ) Pfizer is a leading biopharmaceutical company focused on vaccines and treatments... NYC, US  | ||||
 Earlybird Venture Capital( ) Earlybird is a venture capital investor focusing on Europe’s tech innovators, sp... London  | ||||
 Oxford Science Enterprises( ) The firm focuses on investing in Life Sciences, Health Tech, and Deep Tech, prim... Oxford | ||||
 British Business Bank( ) The British Business Bank focuses on enhancing finance accessibility for smaller... Sheffield | ||||
 Canaan( ) Canaan is an early-stage venture capital firm that focuses on healthcare and tec... San Francisco, US | ||||
 Andera Partners( ) Andera Partners is a private equity firm with €4.5 billion under management, sup... Paris, France  | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK